A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Incyte Corporation
Incyte Corporation
Stanford University
Incyte Corporation
Incyte Corporation
Dana-Farber Cancer Institute
Prelude Therapeutics
City of Hope Medical Center
Incyte Corporation
M.D. Anderson Cancer Center
Mayo Clinic
Dana-Farber Cancer Institute
University of Chicago
Cellenkos, Inc.
Fox Chase Cancer Center